ReviewBreathe (Sheffield, England)2026
The European Respiratory Society guideline for management of adult bronchiectasis: clinical summary.
Review in Breathe (Sheffield, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review provides an overview of the 2025 European Respiratory Society guidelines for adult bronchiectasis. We cover the initial assessment of patients with bronchiectasis to identify the underlying cause, pharmacotherapy including long-term oral and inhaled antibiotic treatment, anti-inflammatory treatments and mucoactive drugs, and non-pharmacological treatments including airway clearance and pulmonary rehabilitation. We provide examples of how to implement the guideline algorithms in practice including how to manage patients during an acute exacerbation and the deteriorating patient. An important component of the new guideline is assessing patients' future risk of exacerbation, which takes into account not just prior history of exacerbations, but also severity of baseline symptoms and additional risk factors such as the underlying cause of bronchiectasis and infection with pathogens like
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.